We aimed to determine the therapeutic efficacy of 0.05% topical cyclosporine A (CsA) for chronic ocular surface disease (OSD) in patients using benzalkonium chloride (BAK)-preserved antiglaucoma eye drops.
Methods:
A prospective, randomized, paired-eye, controlled clinical trial was conducted with participants who had been instilling at least one BAK-preserved topical antiglaucoma drug in both eyes for at least 6 months. Topical CsA was only applied in randomly selected unilateral eyes. Visual field (VF) indices, ocular surface parameters, tear meniscus height (TMH), and matrix metalloproteinase-9 (MMP-9) immunoassay were evaluated at baseline and at 2 and 4 months.
Results:
Seventy eyes from 35 participants were included in the study. The Schirmer I, tear breakup time, and TMH increased by 4.5 ± 8.6 mm (P < 0.01), 5.0 ± 5.3 s (P < 0.001), and 85.4 ± 159.0 μm (P < 0.01) in the treated eyes at 4 months from baseline, respectively. The ocular staining score and MMP-9 positivity in the treated eyes decreased by 2.2 ± 1.3 (P < 0.001) and 0.7 ± 0.9 points (P < 0.001), respectively, at 4 months. In untreated eyes, only TMH increased by 41.4 ± 92.1 μm (P = 0.016) from baseline to 4 months. In VF indices, the tracking failure frequency was 19.09% ± 21.62%, and the test duration was 336.0 ± 79.5 s in the treated eyes at 4 months, which were lower than 34.37% ± 23.13% (P < 0.001) and 375.9 ± 70.7 s (P < 0.05) in the nontreated eyes.
Conclusion:
Application of topical 0.05% CsA significantly improved the OSD parameters and the reliability indices of VF tests. This study was registered with the Clinical Research Information Service (CRIS) (number KCT0007124).
Get full access to this article
View all access options for this article.
References
1.
JonasJB, AungT, BourneRR, et al.Glaucoma. Lancet, 2017; 390(10108):2183–2193; doi: 10.1016/S0140-6736(17)31469-1
StapletonF, AlvesM, BunyaVY, et al.TFOS DEWS II epidemiology report. Ocul Surf, 2017; 15(3):334–365; doi: 10.1016/j.jtos.2017.05.003
4.
MurugesanV, DwivediR, SainiM, et al.Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives. Br J Ophthalmol, 2021; 105(1):141–148; doi: 10.1136/bjophthalmol-2019-314234
5.
MathewsPM, RamuluPY, FriedmanDS, et al.Evaluation of ocular surface disease in patients with glaucoma. Ophthalmology, 2013; 120(11):2241–2248; doi: 10.1016/j.ophtha.2013.03.045
6.
Pérez-BartoloméF, Martínez-de-la-CasaJM, Arriola-VillalobosP, et al.Ocular surface disease in patients under topical treatment for glaucoma. Eur J Ophthalmol, 2017; 27(6):694–704; doi: 10.5301/ejo.5000977
7.
ChaSH, LeeJS, OumBS, et al.Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol, 2004; 32(2):180–184; doi: 10.1111/j.1442-9071.2004.00782.x
8.
DebbaschC, BrignoleF, PisellaPJ, et al.Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci, 2001; 42(3):642–652.
9.
MüllertzO, HedengranA, MouhammadZA, et al.Impact of benzalkonium chloride-preserved and preservative-free latanoprost eye drops on cultured human conjunctival goblet cells upon acute exposure and differences in physicochemical properties of the eye drops. BMJ Open Ophthalmol, 2021; 6(1):e000892; doi: 10.1136/bmjophth-2021-000892
10.
AweOO, OnakpoyaOH, AdeoyeAO. Effect of long-term topical antiglaucoma medication use on the ocular surface. Niger Med J, 2020; 61(4):184–188; doi: 10.4103/nmj.NMJ_116_19
11.
EpsteinSP, ChenD, AsbellPA. Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther, 2009; 25(5):415–424; doi: 10.1089/jop.2008.0140
12.
SherwoodMB, GriersonI, MillarL, et al.Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology, 1989; 96(3):327–335; doi: 10.1016/s0161-6420(89)32888-0
13.
BroadwayDC, GriersonI, O'BrienC, et al.Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol, 1994; 112(11):1446–1454; doi: 10.1001/archopht.1994.01090230060021
14.
WanKH, ChenLJ, YoungAL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: A systematic review and meta-analysis. Ocul Surf, 2015; 13(3):213–225; doi: 10.1016/j.jtos.2014.12.006
15.
RussHH, Nogueira-FilhoPA, Barros JdeN, et al.Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: A randomized clinical trial. Clinics (Sao Paulo), 2013; 68(10):1318–1324; doi: 10.6061/clinics/2013(10)05
16.
CampAS, LongCP, GalorA, et al.Dry eye symptom severity and visual field reliability metrics. J Glaucoma, 2022; 31(5):305–309; doi: 10.1097/IJG.0000000000002017
17.
ÖzyolP, ÖzyolE, KaralezliA. Evaluation of visual field test parameters after artificial tear administration in patients with glaucoma and dry eye. Semin Ophthalmol, 2018; 33(3):320–324; doi: 10.1080/08820538.2016.1238096
18.
KimHS, KimTI, KimJH, et al.Evaluation of clinical efficacy and safety of a novel cyclosporin a nanoemulsion in the treatment of dry eye syndrome. J Ocul Pharmacol Ther, 2017; 33(7):530–538; doi: 10.1089/jop.2016.0164
19.
KangMJ, KimYH, ChouM, et al.Evaluation of the efficacy and safety of a novel 0.05% cyclosporin a topical nanoemulsion in primary Sjögren's syndrome dry eye. Ocul Immunol Inflamm, 2020; 28(3):370–378; doi: 10.1080/09273948.2019.1587470
20.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf, 2007; 5(2):75–92; doi: 10.1016/s1542-0124(12)70081-2
21.
CookJA, BotelloAP, EldersA, et al.Systematic review of the agreement of tonometers with Goldmann applanation tonometry. Ophthalmology, 2012; 119(8):1552–1557; doi: 10.1016/j.ophtha.2012.02.030
22.
WolffsohnJS, AritaR, ChalmersR, et al.TFOS DEWS II diagnostic methodology report. Ocul Surf, 2017; 15(3):539–574; doi: 10.1016/j.jtos.2017.05.001
23.
JunJH, LeeYH, SonMJ, et al.Importance of tear volume for positivity of tear matrix metalloproteinase-9 immunoassay. PLoS One, 2020; 15(7):e0235408; doi: 10.1371/journal.pone.0235408
24.
KimM, OhJY, BaeSH, et al.Assessment of reliability and validity of the 5-scale grading system of the point-of-care immunoassay for tear matrix metalloproteinase-9. Sci Rep, 2021; 11(1):12394; doi: 10.1038/s41598-021-92020-6
25.
LeeYH, BangSP, ShimKY, et al.Association of tear matrix metalloproteinase 9 immunoassay with signs and symptoms of dry eye disease: A cross-sectional study using qualitative, semiquantitative, and quantitative strategies. PLoS One, 2021; 16(10):e0258203; doi: 10.1371/journal.pone.0258203
26.
TashbayevB, UtheimTP, Utheim ØA, et al.Utility of tear osmolarity measurement in diagnosis of dry eye disease. Sci Rep, 2020; 10(1):5542; doi: 10.1038/s41598-020-62583-x
27.
SugisakiK, AsaokaR, InoueT, et al.Predicting Humphrey 10–12 visual field from 24-2 visual field in eyes with advanced glaucoma. Br J Ophthalmol, 2020; 104(5):642–647; doi: 10.1136/bjophthalmol-2019-314170
28.
CampAS, LongCP, PatellaVM, et al.Standard reliability and gaze tracking metrics in glaucoma and glaucoma suspects. Am J Ophthalmol, 2022; 234:91–98; doi: 10.1016/j.ajo.2021.06.038
29.
IshiyamaY, MurataH, MayamaC, et al.An objective evaluation of gaze tracking in Humphrey perimetry and the relation with the reproducibility of visual fields: A pilot study in glaucoma. Invest Ophthal Vis Sci, 2014; 55(12):8149–8152; doi: 10.1167/iovs.14-15541
30.
FaulF, ErdfelderE, LangAG, et al.G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods, 2007; 39(2):175–191; doi: 10.3758/bf03193146
31.
BangSP, YeonCY, AdhikariN, et al.Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model. PLoS One, 2019; 14(11):e0224805; doi: 10.1371/journal.pone.0224805
32.
SainiM, DhimanR, DadaT, et al.Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond), 2015; 29(6):808–814; doi: 10.1038/eye.2015.40
33.
IvakhnitskaiaE, SoubochV, DallacasagrandeV, et al.Benzalkonium chloride, a common ophthalmic preservative, compromises rat corneal cold sensitive nerve activity. Ocular Surf, 2022; 26:88–96; doi: 10.1016/j.jtos.2022.07.012
34.
FogagnoloP, TorregrossaG, TranchinaL, et al.Tear film osmolarity, ocular surface disease and glaucoma: A review. Curr Med Chem, 2019; 26(22):4241–4252; doi: 10.2174/0929867326666190725160621
35.
Szczesna-IskanderDH. Measurement variability of the TearLab osmolarity system. Cont Lens Anterior Eye, 2016; 39(5):353–358; doi: 10.1016/j.clae.2016.06.006
36.
BunyaVY, FuerstNM, PistilliM, et al.Variability of tear osmolarity in patients with dry eye. JAMA Ophthalmol, 2015; 133(6):662–667; doi: 10.1001/jamaophthalmol.2015.0429
37.
GoldsteinMH, SilvaFQ, BlenderN, et al.Ocular benzalkonium chloride exposure: Problems and solutions. Eye (Lond), 2022; 36(2):361–368; doi: 10.1038/s41433-021-01668-x
38.
de PaivaCS, PflugfelderSC, NgSM, et al.Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev, 2019; 9(9):CD010051; doi: 10.1002/14651858.CD010051.pub2
39.
LiangH, BaudouinC, DaullP, et al. Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model. Mol Vis, 2012; 18:2195–2204.
40.
CridgeH, KordonA, PinchukLM, et al.Effects of cyclosporine on feline lymphocytes activated in vitro. Vet Immunol Immunopathol, 2020; 219:109962; doi: 10.1016/j.vetimm.2019.109962
JonesL, DownieLE, KorbD, et al.TFOS DEWS II management and therapy report. Ocul Surf, 2017; 15(3):575–628; doi: 10.1016/j.jtos.2017.05.006
44.
ClarkAF, MiggansST, WilsonK, et al.Cytoskeletal changes in cultured human glaucoma trabecular meshwork cells. J Glaucoma, 1995; 4(3):183–188; doi: 10.1097/00061198-199506000-00007
45.
JohnsonD, GottankaJ, FlügelC, et al.Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol, 1997; 115(3):375–383; doi:10.1001/archopht.1997.01100150377011
46.
DietleinTS, JordanJF, LükeC, et al.Self-application of single-use eyedrop containers in an elderly population: Comparisons with standard eyedrop bottle and with younger patients. Acta Ophthalmol, 2008; 86(8):856–859; doi: 10.1111/j.1755-3768.2007.01155.x
47.
DenisP, DuchS, ChenE, et al.European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment. Eur J Ophthalmol, 2021; 31(3):1056–1063; doi: 10.1177/1120672120919342
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
